Coya is currently conducting the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS ( ...
Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodiesComplete blockade of TL1A binding to DR3 for over 3 months expected at doses of 1 mg/ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results